3D conformal radiation therapy (3DCRT) for high grade prostate cancer: A multi-institutional review

International Journal of Radiation Oncology Biology Physics

Volumn 47, Issue 2, 2000, Pages 335-342

  Fiveash, John B ^a   Hanks, Gerald ^c   Roach III, Mack ^d   Wang, Songbai ^b   Vigneault, Eric ^d   McLaughlin, P William ^b   Sandler, Howard M ^b  

^a UNIVERSITY OF ALABAMA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c FOX CHASE CANCER CENTER   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Dose escalation; Prostate neoplasms; Prostate specific antigen; Three dimensional conformal therapy

Indexed keywords

ARTICLE; CANCER GRADING; DOSE CALCULATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROSTATE ADENOCARCINOMA; RADIATION DOSE; RETROSPECTIVE STUDY; TREATMENT INDICATION; TREATMENT OUTCOME;

ADENOCARCINOMA; AGED; COHORT STUDIES; HUMANS; MALE; MULTICENTER STUDIES; NEOPLASM STAGING; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIOTHERAPY DOSAGE; RADIOTHERAPY, CONFORMAL; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 0034192299     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(00)00441-7     Document Type: Article

References (29)

1. Gleason D.F., Mellinger G.T. Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J Urol. 111:1974;58-64.
2. Roach M 3rd, Lu J, Pilepich MV; et al. Prognostic subgroups predict disease specific survival for men treated with radiotherapy alone on radiation therapy oncology group (RTOG) prostate cancer trials (Abstr.) Proc ASCO 1998;17:312a.
3. Orozco R., O'Dowd G., Kunnel B., et al. Observations on pathology trends in 62,537 prostate biopsies obtained from urology private practices in the United States. Urology. 51:1998;186-195.
4. Steinberg D.M., Sauvageot J., Piantadosi S., et al. Correlation of prostate needle biopsy and radical prostatectomy Gleason grade in academic and community settings. Am J Surg Path. 21:1997;566-576.
5. Kuban D.A., el-Mahdi A.M., Schellhammer P.F. Prostate-specific antigen for pretreatment prediction and posttreatment evaluation of outcome after definitive irradiation for prostate cancer. Int J Radiat Oncol Biol Phys. 32:1995;307-316.
6. Zietman A.L., Coen J.J., Dallow K.C., et al. The treatment of prostate cancer by conventional radiation therapy an analysis of long-term outcome . Int J Radiat Oncol Biol Phys. 32:1995;287-292.
7. Stamey T.A. The central role of prostate specific antigen in diagnosis and progression of prostate cancer. J Urol. 154:1995;1418-1419.
8. Partin A.W., Pound C.R., Clemens J.Q., et al. Serum PSA after anatomic radical prostatectomy. The Johns Hopkins experience after 10 years. Urol Clin N Am. 20:1993;713-725.
9. Roach M. 3rd, Meehan S., Kroll S., et al. Radiotherapy for high grade clinically localized adenocarcinoma of the prostate. J Urol. 156:1996;1719-1723.
10. Sandler H.M., McShan D.L., Lichter A.S. Potential improvement in the results of irradiation for prostate carcinoma using improved dose distribution. Int J Radiat Oncol Biol Phys. 22:1992;361-367.
11. Akazawa P.F., Roach M. 3rd, Pickett B., et al. Three dimensional comparison of blocked arcs vs. four and six field conformal treatment of the prostate. Radiother Oncol. 41:1996;83-88.
12. Weil M.D., Pickett B., Kuerth S., et al. A three-field arc technique (3-FAT) for treating prostate cancer. Int J Radiat Oncol Biol Phys. 40:1998;733-738.
13. Hanks G.E., Hanlon A.L., Schultheiss T.E., et al. Dose escalation with 3D conformal treatment five year outcomes, treatment optimization, and future directions . Int J Radiat Oncol Biol Phys. 41:1998;501-510.
14. Consensus statement guidelines for PSA following radiation therapy . Int J Radiat Oncol Biol Phys. 37:1997;1035-1041.
15. Shipley W.U., Verhey L.J., Munzenrider J.E., et al. Advanced prostate cancer the results of a randomized comparative trial of high dose irradiation boosting with conformal protons compared with conventional dose irradiation using photons alone . Int J Radiat Oncol Biol Phys. 32:1995;3-12.
16. Pollack A., Zagars G.K. External beam radiotherapy dose response of prostate cancer. Int J Radiat Oncol Biol Phys. 39:1997;1011-1018.
17. Pollack A., Zagars G.K., Starkschall G., et al. Conventional vs. conformal radiotherapy for prostate cancer preliminary results of dosimetry and acute toxicity . Int J Radiat Oncol Biol Phys. 34:1996;555-564.
18. Nguyen L.N., Pollack A., Zagars G.K. Late effects after radiotherapy for prostate cancer in a randomized dose-response study results of a self-assessment questionnaire . Urology. 51:1998;991-997.
19. Zelefsky M.J., Leibel S.A., Gaudin P.B., et al. Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer. Int J Radiat Oncol Biol Phys. 41:1998;491-500.
20. Oefelein M.G., Smith N.D., Grayhack J.T., et al. Long-term results of radical retropubic prostatectomy in men with high grade carcinoma of the prostate. J Urol. 158:1997;1460-1465.
21. Partin A.W., Lee B.R., Carmichael M., et al. Radical prostatectomy for high grade disease a reevaluation 1994 . J Urol. 151:1994;1583-1586.
22. Ohori M., Goad J.R., Wheeler T.M., et al. Can radical prostatectomy alter the progression of poorly differentiated prostate cancer? J Urol. 152:1994;1843-1849.
23. Lu-Yao G.L., Potosky A.L., Albertsen P.C., et al. Follow-up prostate cancer treatments after radical prostatectomy a population-based study . J Natl Cancer Inst. 88:1996;166-173.
24. Perrotti M., Farhang R., Russo P., et al. Early prostate cancer detection and potential for cure in men with poorly diffentiated tumors. Urology. 52:1998;106-110.
25. Pilepich M.V., Caplan R., Byhardt R.W., et al. Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy report of Radiation Therapy Oncology Group Protocol 85-31 . J Clin Oncol. 15:1997;1013-1021.
26. Bolla M., Gonzalez D., Warde P., et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med. 337:1997;295-300.
27. Leibel S.A., Hanks G.E., Kramer S. Patterns of care outcome studies results of the national practice in adenocarcinoma of the prostate . Int J Radiat Oncol Biol Phys. 10:1984;401-409.
28. Sandler H.M., McLaughlin P.W., Ten Haken R.K., et al. Three dimensional conformal radiotherapy for the treatment of prostate cancer low risk of chronic rectal morbidity observed in a large series of patients . Int J Radiat Oncol Biol Phys. 33:1995;797-801.
29. Lee W.R., Hanks G.E., Hanlon A.L., et al. Lateral rectal shielding reduces late rectal morbidity following high dose three-dimensional conformal radiation therapy for clinically localized prostate cancer further evidence for a significant dose effect . Int J Radiat Oncol Biol Phys. 35:1996;251-257.